Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Ophthalmology

Monitoring Your Health: The Long Road Ahead

At a Glance

Long-term AAION and GCA care includes a slow steroid taper, attention to relapse symptoms even when blood tests are normal, vascular imaging for large-vessel complications, monitoring steroid side effects, and rehabilitation to protect independence after vision loss.

Managing Arteritic Anterior Ischemic Optic Neuropathy (AAION) and Giant Cell Arteritis (GCA) is a marathon, not a sprint [1]. Even after the initial emergency has passed, you will need a structured monitoring plan that continues long after you take your last dose of steroids [1]. This phase of your journey focuses on preventing relapses, watching for long-term complications, and adapting to any changes in your sight.

Navigating the Steroid Taper and Relapses

To control the inflammation, your doctors will slowly reduce your steroid dose over several months or even years [1][2]. This “tapering” is a delicate process because relapses are very common—affecting roughly 34% to 50% of patients [2][3]. Most relapses happen within the first two years, often while you are still taking a low dose of steroids [2].

It is critical to know that you cannot rely on blood tests alone to monitor for a relapse [4]. In about 21% of cases, both the ESR and CRP markers remain completely normal even when the disease has become active again [2]. If you are taking tocilizumab, these blood tests are even less reliable [5][6].

You must watch for these “Return of Disease” symptoms:

  • New or returning headaches or scalp tenderness [4].
  • Jaw or tongue pain when chewing or speaking [4].
  • Return of Polymyalgia Rheumatica (stiff, achy shoulders or hips, especially in the morning) [4].
  • Any new visual changes, even brief “flickers” [4].

Protecting Your Arteries Long-Term

Because GCA is an inflammation of the larger blood vessels, it can cause structural damage over time, even if you feel well [7]. The most serious long-term risk is an aortic aneurysm—a dangerous “bulge” in the body’s main artery [8][9].

These complications often develop years after the initial diagnosis [9][10]. Baseline noninvasive vascular imaging (like MRA, CTA, or PET/CT) is commonly recommended for newly diagnosed GCA to check for large-vessel involvement [11][12]. Your doctor will determine how often you need repeated scans based on your specific risks and symptoms [11].

Managing Long-Term Steroid Side Effects

While high-dose steroids (glucocorticoids) are life-saving for your vision, they carry significant side effects over the long term [13]. Your medical team will monitor you for:

  • Medication Safety: Never stop or change your steroid dose abruptly without medical advice. Ask about sick-day instructions and consider a medical-alert card because prolonged treatment can suppress adrenal function.
  • Bone Health: Steroids significantly increase the risk of osteoporosis and fractures [14][13]. You may need bone density scans and medications to protect your bones [15].
  • Metabolic Changes: Long-term use can lead to weight gain, high blood pressure, and type 2 diabetes [14][13].
  • Eye Health: Steroids increase the risk of developing cataracts and glaucoma (high pressure in the eye) [14][13].
  • Infection Risk: Your immune system may be weakened, making it harder to fight off infections [14][16].

Adjusting to Life with AAION

If AAION has caused permanent vision loss in one eye, you are now navigating life with monocular vision (one-eyed vision) [17]. This can affect your depth perception, balance, and peripheral awareness [18].

Low-vision rehabilitation and occupational therapy are essential resources for regaining your independence [19][20]. These specialists can help you with:

  • Protecting Your Good Eye: Wear protective eyewear for the remaining eye.
  • Home Safety: Modifying your home to prevent falls [20].
  • Daily Tasks: Training in “scanning” techniques to make the most of your remaining vision and using assistive technology for reading and cooking [20][21].
  • Emotional Support: It is normal to experience anxiety or depression following sudden vision loss [22][23]. Counseling and peer support groups can help you process the grief and regain a sense of autonomy [24][25].

Remember, while the vision loss from AAION is often permanent, the inflammation of GCA can be managed [1]. By staying vigilant for symptoms and working closely with your care team, you can protect your remaining vision and your overall health [26].

Common questions in this guide

How slowly should steroid treatment be reduced for AAION and GCA?
Steroids are usually reduced gradually over months or sometimes years because giant cell arteritis can flare during tapering and prolonged treatment can suppress the body’s own steroid production. Your clinician should set the schedule; never stop or change the dose on your own.
What does a GCA relapse feel like if my blood tests are normal?
A relapse may cause a new or returning headache or scalp tenderness, jaw or tongue pain with chewing or speaking, morning shoulder or hip stiffness, or any new visual change. Blood tests such as ESR and CRP can remain normal, and tocilizumab can make them less reliable, so new symptoms should be discussed promptly with your care team.
Why might I need MRA, CTA, or PET/CT after a GCA diagnosis?
These noninvasive scans look for large-vessel involvement and structural problems that can include an aortic aneurysm. A baseline scan is commonly considered when GCA is diagnosed, and the timing of repeat imaging depends on your symptoms and individual risk.
What steroid side effects should be checked over time?
Long-term steroids can weaken bones, raise blood pressure or blood sugar, cause weight gain, increase the risk of cataracts, glaucoma, and infections, and suppress adrenal function. Your care team may monitor bone density, eye health, metabolic measures, and infection risk, and can discuss bone-protective treatment.
How can I adapt to losing vision in one eye from AAION?
Low-vision rehabilitation and occupational therapy can help with depth perception, balance, scanning, reading, cooking, and other daily tasks. Protective eyewear, home safety changes, assistive technology, counseling, and peer support can also help you remain independent.
Is vision loss from AAION permanent?
Vision loss from AAION is often permanent, although the outlook varies by person and the amount of damage. Treating and monitoring GCA can help control inflammation and protect the vision that remains.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my specific 'taper schedule' for reducing my steroid dose, and what should I do if my symptoms return during a taper?
  2. 2.Since my blood tests can be normal even during a relapse, what specific physical symptoms should I be watching for most closely?
  3. 3.When is my next vascular imaging (like an MRA or CTA) scheduled to check for an aortic aneurysm?
  4. 4.What is our long-term plan for protecting my bone density while I am on steroids?
  5. 5.Can you refer me to a low-vision rehabilitation specialist who can help me adapt to my vision changes?
  6. 6.Should I be screened for cataracts or glaucoma as a side effect of my long-term steroid use?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (26)
  1. 1

    [Treatment of giant cell arteritis and polymyalgia rheumatica].

    Horvath L, Hellmich B

    Zeitschrift fur Rheumatologie 2020; (79(2)):175-185 doi:10.1007/s00393-020-00754-x.

    PMID: 32078029
  2. 2

    Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study.

    Kermani TA, Warrington KJ, Cuthbertson D, et al.

    The Journal of rheumatology 2015; (42(7)):1213-7 doi:10.3899/jrheum.141347.

    PMID: 25877501
  3. 3

    Management of Relapses in Giant Cell Arteritis.

    Alba MA, Unizony S, Warrington KJ, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2025; (77(6)):632-645 doi:10.1002/art.43098.

    PMID: 39711085
  4. 4

    Epidemiology of major relapse in giant cell arteritis: A study-level meta-analysis.

    Aussedat M, Lobbes H, Samson M, et al.

    Autoimmunity reviews 2022; (21(1)):102930 doi:10.1016/j.autrev.2021.102930.

    PMID: 34481940
  5. 5

    Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab.

    Stone JH, Tuckwell K, Dimonaco S, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2019; (71(8)):1329-1338 doi:10.1002/art.40876.

    PMID: 30835950
  6. 6

    Recent advances in the diagnosis and management of giant cell arteritis.

    Serling-Boyd N, Stone JH

    Current opinion in rheumatology 2020; (32(3)):201-207 doi:10.1097/BOR.0000000000000700.

    PMID: 32168069
  7. 7

    The clinical benefit of imaging in the diagnosis and treatment of giant cell arteritis.

    Berger CT, Sommer G, Aschwanden M, et al.

    Swiss medical weekly 2018; (148()):w14661.

    PMID: 30141518
  8. 8

    Large vessel giant cell arteritis.

    van der Geest KSM, Sandovici M, Bley TA, et al.

    The Lancet. Rheumatology 2024; (6(6)):e397-e408 doi:10.1016/S2665-9913(23)00300-4.

    PMID: 38574745
  9. 9

    18F-fluorodeoxyglucose positron emission tomography and the risk of subsequent aortic complications in giant-cell arteritis: A multicenter cohort of 130 patients.

    de Boysson H, Liozon E, Lambert M, et al.

    Medicine 2016; (95(26)):e3851 doi:10.1097/MD.0000000000003851.

    PMID: 27367985
  10. 10

    Symptomatic aortitis at giant cell arteritis diagnosis: a prognostic factor of aortic event.

    Espitia O, Blonz G, Urbanski G, et al.

    Arthritis research & therapy 2021; (23(1)):14 doi:10.1186/s13075-020-02396-5.

    PMID: 33413605
  11. 11

    EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update.

    Dejaco C, Ramiro S, Bond M, et al.

    Annals of the rheumatic diseases 2024; (83(6)):741-751 doi:10.1136/ard-2023-224543.

    PMID: 37550004
  12. 12

    French recommendations for the use of imaging in giant cell arteritis.

    Espitia O, de Boysson H, Heron E, et al.

    Joint bone spine 2026; (93(5)):106073 doi:10.1016/j.jbspin.2026.106073.

    PMID: 42107587
  13. 13

    Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis.

    Wilson JC, Sarsour K, Collinson N, et al.

    Seminars in arthritis and rheumatism 2017; (46(6)):819-827 doi:10.1016/j.semarthrit.2016.11.006.

    PMID: 28040244
  14. 14

    Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis.

    Wilson JC, Sarsour K, Collinson N, et al.

    Seminars in arthritis and rheumatism 2017; (46(5)):650-656 doi:10.1016/j.semarthrit.2016.10.001.

    PMID: 27839741
  15. 15

    Prognostic impacts of glucocorticoid treatment in patients with polymyalgia rheumatica and giant cell arteritis.

    Emamifar A, Ellingsen T, Hermann AP, et al.

    Scientific reports 2021; (11(1)):6220 doi:10.1038/s41598-021-85857-4.

    PMID: 33737697
  16. 16

    Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice.

    Calderón-Goercke M, Loricera J, Aldasoro V, et al.

    Seminars in arthritis and rheumatism 2019; (49(1)):126-135 doi:10.1016/j.semarthrit.2019.01.003.

    PMID: 30655091
  17. 17

    Orbital magnetic resonance imaging of giant cell arteritis with ocular manifestations: a systematic review and individual participant data meta-analysis.

    Guggenberger KV, Pavlou A, Cao Q, et al.

    European radiology 2023; (33(11)):7913-7922 doi:10.1007/s00330-023-09770-2.

    PMID: 37256352
  18. 18

    Importance of Screening for Contrast Sensitivity, Falls, and Mobility Limitations in Older Adults With Maculopathy.

    Agathos CP, Shanidze NM, Fletcher DC

    American journal of ophthalmology 2025; (280()):481-492 doi:10.1016/j.ajo.2025.08.051.

    PMID: 40889625
  19. 19

    Developing consensus-based referral criteria for low vision services in Australia.

    Alam K, Connor H, Gentle A, Bentley SA

    Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) 2022; (42(1)):149-160 doi:10.1111/opo.12902.

    PMID: 34637155
  20. 20

    Low vision home therapy service by occupational therapists: The effectiveness of the Seniors' Eye Rehabilitation programme, a pilot study.

    Tan Y, Sim Tan AC, Hui JHS, et al.

    The British journal of occupational therapy 2023; (86(5)):359-366 doi:10.1177/03080226231153340.

    PMID: 40336517
  21. 21

    Outcomes of the Veterans Affairs Low Vision Intervention Trial II (LOVIT II): A Randomized Clinical Trial.

    Stelmack JA, Tang XC, Wei Y, et al.

    JAMA ophthalmology 2017; (135(2)):96-104 doi:10.1001/jamaophthalmol.2016.4742.

    PMID: 27978569
  22. 22

    Association Between Visual Impairment and Depression in Patients Attending Eye Clinics: A Meta-analysis.

    Parravano M, Petri D, Maurutto E, et al.

    JAMA ophthalmology 2021; (139(7)):753-761 doi:10.1001/jamaophthalmol.2021.1557.

    PMID: 34042966
  23. 23

    Visual impairment and psychological distress among adults attending the University of Gondar tertiary eye care and training center, Northwest Ethiopia: A comparative cross-sectional study.

    Munaw MB, Tegegn MT

    PloS one 2022; (17(2)):e0264113 doi:10.1371/journal.pone.0264113.

    PMID: 35176097
  24. 24

    Stepped care for depression and anxiety in visually impaired older adults: multicentre randomised controlled trial.

    van der Aa HP, van Rens GH, Comijs HC, et al.

    BMJ (Clinical research ed.) 2015; (351()):h6127 doi:10.1136/bmj.h6127.

    PMID: 26597263
  25. 25

    Understanding healthcare communication in age-related macular degeneration care: A mixed-methods review of patients' perspectives.

    Scheffer M, Menting J, Boeije H, et al.

    Survey of ophthalmology 2024; (69(4)):646-660 doi:10.1016/j.survophthal.2024.03.002.

    PMID: 38499047
  26. 26

    Prognosis and monitoring of giant cell arteritis and associated complications.

    Kermani TA, Warrington KJ

    Expert review of clinical immunology 2018; (14(5)):379-388 doi:10.1080/1744666X.2018.1467758.

    PMID: 29676201

This page is for informational purposes only and does not constitute medical advice about AAION or giant cell arteritis. Do not change steroid treatment or delay evaluation of new symptoms without contacting your healthcare team.

Get notified when new evidence is published on arteritic anterior ischemic optic neuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.